These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 25283984)

  • 1. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
    Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
    Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS.
    Koch JC; Tönges L; Barski E; Michel U; Bähr M; Lingor P
    Cell Death Dis; 2014 May; 5(5):e1225. PubMed ID: 24832597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease.
    Walsh S; Gavin A; Wyatt S; O'Connor C; Keeshan K; Nolan YM; O'Keeffe GW; Sullivan AM
    Int J Neurosci; 2015 Jan; 125(1):70-7. PubMed ID: 24628580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
    Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
    Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
    Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
    Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV-mediated expression of BAG1 and ROCK2-shRNA promote neuronal survival and axonal sprouting in a rat model of rubrospinal tract injury.
    Challagundla M; Koch JC; Ribas VT; Michel U; Kügler S; Ostendorf T; Bradke F; Müller HW; Bähr M; Lingor P
    J Neurochem; 2015 Jul; 134(2):261-75. PubMed ID: 25807858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat.
    Dass B; Iravani MM; Huang C; Barsoum J; Engber TM; Galdes A; Jenner P
    J Neural Transm (Vienna); 2005 Jun; 112(6):763-78. PubMed ID: 15586304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
    Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
    Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
    Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
    Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
    Decressac M; Mattsson B; Björklund A
    Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
    Han B; Jin HJ; Song MY; Wang T; Zhao H
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
    Manfredsson FP; Burger C; Sullivan LF; Muzyczka N; Lewin AS; Mandel RJ
    Exp Neurol; 2007 Oct; 207(2):289-301. PubMed ID: 17678648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAV-mediated inhibition of ULK1 promotes axonal regeneration in the central nervous system in vitro and in vivo.
    Ribas VT; Vahsen BF; Tatenhorst L; Estrada V; Dambeck V; Almeida RA; Bähr M; Michel U; Koch JC; Müller HW; Lingor P
    Cell Death Dis; 2021 Feb; 12(2):213. PubMed ID: 33637688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.
    Pranski EL; Dalal NV; Sanford CV; Herskowitz JH; Gearing M; Lazo C; Miller GW; Lah JJ; Levey AI; Betarbet RS
    Neurobiol Dis; 2013 Jun; 54():264-79. PubMed ID: 23318928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats.
    Kolasiewicz W; Kuter K; Berghauzen K; Nowak P; Schulze G; Ossowska K
    Brain Res; 2012 Oct; 1477():59-73. PubMed ID: 22902616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.